Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
63.89%
Operating Margin
18.97%
Net Margin
15.44%
Efficiency Metrics
Revenue per Expense Ratio
1.23
R&D as % of Revenue
6.77%
Earnings Quality
EBITDA Margin
24.07%
Income Tax Rate
13.83%
EPS
8.3400000000
Balance Sheet Analysis
Current Ratio
1.58
Cash Ratio
0.39
Working Capital
$4.60B
Debt to Equity
0.70
Debt to Assets
32.56%
Equity Ratio
46.58%
Cash Flow Analysis
Operating Cash Flow Ratio
18.10%
Free Cash Flow Ratio
15.30%
CapEx to Revenue
2.81%
Dividends Paid
$1.14B
Stock Buybacks
$155.00M
Total Shareholder Returns
$1.29B
Cash Position Change
61.12%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 7.97%
Detailed Growth Metrics
Core Performance
Revenue
11.11%
Net Income
34.22%
EPS
33.87%
Operating Income
36.85%
Operational Efficiency
R&D Expenses
-4.54%
SG&A Expenses
7.20%
Operating Cash Flow
41.43%
Free Cash Flow
54.03%
Balance Sheet Health
Assets
8.21%
Debt
-0.41%
Book Value per Share
11.49%
Inventory
21.23%
Shareholder Returns
Dividends per Share
7.97%
Shares Outstanding
0.37%
Long Term Trends
3Y Revenue/Share
41.29%
5Y Revenue/Share
48.53%
3Y Dividend/Share
30.56%
5Y Dividend/Share
59.67%